These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 22807204)

  • 1. Spending functions and continuous-monitoring boundaries.
    Proschan MA; Lan KK
    Stat Med; 2012 Nov; 31(25):3024-30. PubMed ID: 22807204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal spending functions for asymmetric group sequential designs.
    Anderson KM
    Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trials.
    Stone A
    Pharm Stat; 2010; 9(2):151-61. PubMed ID: 19771540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of spending functions for occasional or continuous monitoring of data in clinical trials.
    Lan KK; Rosenberger WF; Lachin JM
    Stat Med; 1993 Dec; 12(23):2219-31. PubMed ID: 8310191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementing type I & type II error spending for two-sided group sequential designs.
    Rudser KD; Emerson SS
    Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stopping guidelines for harm in a study designed to establish the safety of a marketed drug.
    Fleishman AN; Parker RA
    J Biopharm Stat; 2012; 22(2):338-50. PubMed ID: 22251178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the timing of a futility analysis in clinical trials.
    Pallay A
    J Biopharm Stat; 2000 Aug; 10(3):399-405. PubMed ID: 10959919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fitting spending functions.
    Anderson KM; Clark JB
    Stat Med; 2010 Feb; 29(3):321-7. PubMed ID: 19842091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How much do we have to pay for how many interim analyses?
    Koch A
    Contemp Clin Trials; 2005 Feb; 26(1):113-6. PubMed ID: 15837456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the spending function method and the Christmas tree correction for group sequential trials.
    Stallard N; Facey KM
    J Biopharm Stat; 1996 Jul; 6(3):361-73. PubMed ID: 8854238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of adaptive designs: efficiency evaluation.
    Menon S; Chang M
    J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An additive boundary for group sequential designs with connection to conditional error.
    Xi D; Gallo P
    Stat Med; 2019 Oct; 38(23):4656-4669. PubMed ID: 31338847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some drop-the-loser designs for monitoring multiple doses.
    Joshua Chen YH; Demets DL; Gordon Lan KK
    Stat Med; 2010 Jul; 29(17):1793-807. PubMed ID: 20658548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints.
    Jennison C; Turnbull BW
    Biometrics; 1993 Sep; 49(3):741-52. PubMed ID: 8241370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The use of state of the art statistical methodology in biomedical research: the example of methodology for interim analyses in clinical trials].
    Muñoz SR; Bangdiwala SI
    Rev Med Chil; 2001 Sep; 129(9):983-8. PubMed ID: 11725478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a continuous stopping boundary from an alpha spending function.
    Betensky RA
    Biometrics; 1998 Sep; 54(3):1061-71. PubMed ID: 9750252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computations for group sequential boundaries using the Lan-DeMets spending function method.
    Reboussin DM; DeMets DL; Kim KM; Lan KK
    Control Clin Trials; 2000 Jun; 21(3):190-207. PubMed ID: 10822118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.